Astellas doses first patient in phase 3 VMS trial of fezolinetant

Japanese pharma company Astellas Pharma has dosed the first patient in the SKYLIGHT 1 phase 3 trial for fezolinetant, an investigational oral, non-hormonal compound for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. Vasomotor symptoms are hot flashes and night sweats which occur in nearly 57% on women, aged 40-64 years as per […]

The post Astellas doses first patient in phase 3 VMS trial of fezolinetant appeared first on PharmaNewsDaily.com.

Japanese pharma company Astellas Pharma has dosed the first patient in the SKYLIGHT 1 phase 3 trial for fezolinetant, an investigational oral, non-hormonal compound for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause.

Vasomotor symptoms are hot flashes and night sweats which occur in nearly 57% on women, aged 40-64 years as per Makara-Studzińśka MT, Kryś-Noszczyk KM, Jakiel G. Epidemiology of the symptoms of menopause – an intercontinental review.

Fezolinetant has been designed to be a selective neurokinin-3 (NK3) receptor antagonist. The non-hormonal compound functions by preventing neurokinin B (NKB) signaling and normalizing KNDy (kisspeptin/NKB/dynorphin) neuron activity, which regulates the temperature control center and lowers the frequency and severity of hot flashes.

See also  Liquidia Corporation shares soar 13% following dual financing announcement

SKYLIGHT 1 marks the first trial of the BRIGHT SKY clinical development program that will assess the efficacy and safety of 30 and 45 mg once-daily (QD) fezolinetant in reducing the frequency and severity of vasomotor symptoms.

Astellas doses first patient in phase 3 VMS trial of fezolinetant

Astellas doses first patient in phase 3 VMS trial of fezolinetant. Photo courtesy of Stuart Miles/Freedigitalphotos.net.

Salim Mujais – Senior Vice President and Therapeutic Area Head, Medical Specialties of Astellas Pharma said: “There are currently limited non-hormonal options for managing vasomotor symptoms, which can be quite disruptive and often interfere with daily life.

See also  Oncternal Therapeutics launches Phase 1b trial of Cirmtuzumab in combination with Paclitaxel in breast cancer

“With the initiation of our Phase 3 fezolinetant program, we move further towards our goal of providing women with a non-hormonal treatment for moderate-to-severe hot flashes.”

Related posts

See also  Allergan to acquire Bonti in strategic $195m deal to expand medical aesthetics pipeline

The post Astellas doses first patient in phase 3 VMS trial of fezolinetant appeared first on PharmaNewsDaily.com.


Discover more from Business-News-Today.com

Subscribe to get the latest posts sent to your email.

Related Posts

CATEGORIES
Share This